Global Blood Therapeutics Inc (NASDAQ:GBT) – Equities researchers at Piper Jaffray Companies issued their Q3 2020 earnings estimates for Global Blood Therapeutics in a research report issued to clients and investors on Thursday, May 16th. Piper Jaffray Companies analyst D. Brill expects that the company will post earnings per share of ($0.91) for the quarter. Piper Jaffray Companies also issued estimates for Global Blood Therapeutics’ Q4 2020 earnings at ($0.58) EPS.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.07.
Shares of NASDAQ:GBT opened at $56.75 on Monday. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $62.50. The company has a quick ratio of 14.38, a current ratio of 14.51 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of -16.64 and a beta of 2.10.
Several large investors have recently made changes to their positions in the stock. FMR LLC grew its stake in shares of Global Blood Therapeutics by 1.1% during the 1st quarter. FMR LLC now owns 8,417,709 shares of the company’s stock valued at $445,549,000 after acquiring an additional 88,310 shares during the period. Perceptive Advisors LLC grew its stake in shares of Global Blood Therapeutics by 1.8% during the 1st quarter. Perceptive Advisors LLC now owns 5,525,726 shares of the company’s stock valued at $292,476,000 after acquiring an additional 100,000 shares during the period. BlackRock Inc. boosted its stake in Global Blood Therapeutics by 1.2% in the 1st quarter. BlackRock Inc. now owns 4,276,943 shares of the company’s stock worth $226,379,000 after purchasing an additional 50,598 shares during the period. Vanguard Group Inc. boosted its stake in Global Blood Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 4,202,443 shares of the company’s stock worth $159,693,000 after purchasing an additional 108,137 shares during the period. Finally, Bank of America Corp DE boosted its stake in Global Blood Therapeutics by 75.6% in the 4th quarter. Bank of America Corp DE now owns 2,543,161 shares of the company’s stock worth $104,397,000 after purchasing an additional 1,094,742 shares during the period.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Recommended Story: Discount Rate
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.